WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997014791) ANIMALS WITH TARGETED GENE DELETION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/014791    International Application No.:    PCT/US1996/016807
Publication Date: 24.04.1997 International Filing Date: 18.10.1996
Chapter 2 Demand Filed:    12.05.1997    
IPC:
C12N 9/12 (2006.01), C12N 15/85 (2006.01)
Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 1345 Avenue of the Americas, New York, NY 10105 (US).
WALTER & ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; Royal Melbourne Hospital, Royal Parade, Parkville, VIC 3050 (AU).
AUSTIN AND REPATRIATION MEDICAL CENTER [AU/AU]; Dept. of Anatomical Pathology, Studley Road, Heidelberg, VIC 3084 (AU)
Inventors: HIBBS, Margaret, L.; (AU).
DUNN, Ashley, R.; (AU).
GRAILL, Dianne; (AU).
HODGSON, George; (AU).
TARLINGTON, David, M.; (AU).
ARMES, Jane; (AU)
Agent: KOHLI, Vineet; Felfe & Lynch, 805 Third Avenue, New York, NY 10022 (US)
Priority Data:
60/005,758 20.10.1995 US
Title (EN) ANIMALS WITH TARGETED GENE DELETION
(FR) ANIMAUX A DELETION CIBLEE DE GENE
Abstract: front page image
(EN)A non-human animal carrying a disruption of a gene encoding a lyn protein tyrosine kinase provides a convenient system for the study of diseases associated with or caused by lyn deficiency, and for the testing of therapeutic agents for the treatment or prevention of diseases which include autoimmune diseases, allergy, asthma and malignant disease.
(FR)Un animal porteur d'une disruption d'un gène codant une protéine tyrosine kinase de lyn constitue un système commode pour l'étude de maladies associées à la déficience du lyn ou causées par elle ainsi que pour l'expérimentation d'agents thérapeutiques destinés au traitement ou à la prévention de maladies comprenant les maladies auto-immunes, l'allergie, l'asthme et les affections malignes.
Designated States: CA.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)